331 related articles for article (PubMed ID: 34972967)
1. Immunotherapy for Neuro-oncology.
Majd NK; Dasgupta PR; de Groot JF
Adv Exp Med Biol; 2021; 1342():233-258. PubMed ID: 34972967
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for Neuro-Oncology.
Majd N; Dasgupta P; de Groot J
Adv Exp Med Biol; 2020; 1244():183-203. PubMed ID: 32301015
[TBL] [Abstract][Full Text] [Related]
3. Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastoma.
Majd N; de Groot J
Expert Opin Pharmacother; 2019 Sep; 20(13):1609-1624. PubMed ID: 31264484
[No Abstract] [Full Text] [Related]
4. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
Medikonda R; Pant A; Lim M
Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
[TBL] [Abstract][Full Text] [Related]
5. A review of glioblastoma immunotherapy.
Medikonda R; Dunn G; Rahman M; Fecci P; Lim M
J Neurooncol; 2021 Jan; 151(1):41-53. PubMed ID: 32253714
[TBL] [Abstract][Full Text] [Related]
6. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
7. Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models.
Koch MS; Zdioruk M; Nowicki MO; Griffith AM; Aguilar E; Aguilar LK; Guzik BW; Barone F; Tak PP; Tabatabai G; Lederer JA; Chiocca EA; Lawler S
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017150
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for Glioblastoma: Current Progress and Challenges.
Yu MW; Quail DF
Front Immunol; 2021; 12():676301. PubMed ID: 34054867
[TBL] [Abstract][Full Text] [Related]
9. Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.
Kreatsoulas D; Bolyard C; Wu BX; Cam H; Giglio P; Li Z
J Hematol Oncol; 2022 Jun; 15(1):80. PubMed ID: 35690784
[TBL] [Abstract][Full Text] [Related]
10. mRNA-based precision targeting of neoantigens and tumor-associated antigens in malignant brain tumors.
Trivedi V; Yang C; Klippel K; Yegorov O; von Roemeling C; Hoang-Minh L; Fenton G; Ogando-Rivas E; Castillo P; Moore G; Long-James K; Dyson K; Doonan B; Flores C; Mitchell DA
Genome Med; 2024 Jan; 16(1):17. PubMed ID: 38268001
[TBL] [Abstract][Full Text] [Related]
11. The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy.
Desland FA; Hormigo A
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027976
[TBL] [Abstract][Full Text] [Related]
12. Present and Future of Immunotherapy in Patients With Glioblastoma: Limitations and Opportunities.
Maccari M; Baek C; Caccese M; Mandruzzato S; Fiorentino A; InternĂ² V; Bosio A; Cerretti G; Padovan M; Idbaih A; Lombardi G
Oncologist; 2024 Apr; 29(4):289-302. PubMed ID: 38048782
[TBL] [Abstract][Full Text] [Related]
13. Current Advances in Immunotherapy for Glioblastoma.
Mende AL; Schulte JD; Okada H; Clarke JL
Curr Oncol Rep; 2021 Jan; 23(2):21. PubMed ID: 33496872
[TBL] [Abstract][Full Text] [Related]
14. Nucleic acid immunotherapeutics and vaccines: A promising approach to glioblastoma multiforme treatment.
Dain L; Zhu G
Int J Pharm; 2023 May; 638():122924. PubMed ID: 37037396
[TBL] [Abstract][Full Text] [Related]
15. Glioblastoma Immune Landscape and the Potential of New Immunotherapies.
Daubon T; Hemadou A; Romero Garmendia I; Saleh M
Front Immunol; 2020; 11():585616. PubMed ID: 33154756
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of Glioblastoma: Current Strategies and Challenges in Tumor Model Development.
Majc B; Novak M; Kopitar-Jerala N; Jewett A; Breznik B
Cells; 2021 Jan; 10(2):. PubMed ID: 33572835
[TBL] [Abstract][Full Text] [Related]
17. Combination immunotherapy strategies for glioblastoma.
Chan HY; Choi J; Jackson C; Lim M
J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
[TBL] [Abstract][Full Text] [Related]
18. Immunological Aspects of Malignant Gliomas.
Cohen-Inbar O; Zaaroor M
Can J Neurol Sci; 2016 Jul; 43(4):494-502. PubMed ID: 27324313
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulation for glioblastoma.
Reardon DA; Wen PY; Wucherpfennig KW; Sampson JH
Curr Opin Neurol; 2017 Jun; 30(3):361-369. PubMed ID: 28368867
[TBL] [Abstract][Full Text] [Related]
20. Extrinsic factors associated with the response to immunotherapy in glioblastoma.
Bi H; Zhang C
Cancer Lett; 2021 Jul; 511():47-55. PubMed ID: 33933551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]